While many western countries are pioneering safe delivery of more cancer care in primary, community and home settings, across central and eastern Europe, beds in university hospitals and cancer centres are still filled unnecessarily with [more]
A huge gap in the Hellenic Organization for Health Care Services Provision reimbursement system (EOPPY) for cancer biomarkers is causing a lot of trouble for doctors and patients. At the moment the Ministry of health [more]
After the European Medicines Agency (EMA) approves a new cancer drug, reimbursement decisions by each country’s health authorities can take up to one year, with wide variations between countries. according to a study just presented [more]
Little by little, patient advocates are winning their battle to be involved in decisions that affect them. They are now focusing on how to use their new-found voice to deliver real change for the people [more]